Download Deep Brain Stimulation to Treat Alzheimer`s Disease

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
John Paquet III
BME 181 S01
08 April 2013

2008 – 7.6 million deaths worldwide by cancer

13% of total worldwide deaths that year

CD47- protein that coats surface of cells

“Don’t eat me” signal to immune cells

Cancer cells boost their CD47 levels

Macrophages ignore the cancer

Blocking monoclonal anti-humanCD47 antibodies

Anti-hCD47 mAbs- include B6H12.2 and Bric126

Anti-hCD47 mAbs block CD47’s “don’t eat me”
signal






SIRPα on macrophages binds to CD47
Resulting signaling cascade inhibits phagocytosis
Anti-hCD47 mAb specifically binds to antigen CD47
to block “don’t eat me” signal
Cancer cells also output “eat me” signal- calreticulin
Disabling CD47 barrier exposes calreticulin “eat me”
signal
Normal cells do not have calreticulin on surface, so
macrophages don’t consume them

In one mouse, human leukemic cancer was completely
gone 1 day after single dose of antibody injected

In mice with human acute myelogenous leukemia,
cancer was erased in a majority of the mice

Large tumors shrink, some smaller ones even vanish

Also successful at treating cancers that have already
spread

Anti-hCD47 mAbs prevent cancer from metastasizing

Greater the amount of CD47 expressed by cancer cells,
the lesser the chance that subject survived
◦ Dosage can be increased

Effectiveness of antibody therapy was inversely
proportional to initial tumor size

Large doses of anti-hCD47 mAbs produce temporary
amenia
◦ Red blood cell count recovers quickly

Not advisable after chemotherapy
◦ Normal cells are damaged due to high stress, so they have
calreticulin on surface- “eat me” signal
◦ Disabling CD47 would enable phagocytosis of normal cells


Can be grown in unlimited amounts
would likely be most effective when:
◦ tumor is maximally debulked
◦ used alongside antibodies that strengthen the “eat me” signals
from surface proteins like calreticulin



Potential to treat nearly every type of cancer
$20 million grant from CIRM
Human trials to begin late 2013
or early 2014





"Cancer." World Health Organization, Jan. 2013. Web.
<http://www.who.int/mediacentre/factsheets/fs297/en/>
"Monoclonal Antibodies." Wikipedia. Wikimedia Foundation, 29 Mar. 2013. Web.
<http://en.wikipedia.org/wiki/Monoclonal_antibodies>
"The CD47-signal Regulatory Protein Alpha (SIRPa) Interaction Is a Therapeutic
Target for Human Solid Tumors." PubMed Central. National Academy of Sciences,
26 Mar. 2012. Web. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340046/>
Vaughan, Christopher. "Cancer Roundhouse: Evidence Mounts That a Single
Antibody Could Knock out Many Cancers." Stanford Medicine, Summer 2012.
Web. <http://stanmed.stanford.edu/2012summer/article7.html>
Weiss, Jonathan. "Scientists Have Silver Bullet To Kill Multiple Cancers, Human
Trials Starting." Medical Daily, 28 Mar. 2013. Web.
<http://www.medicaldaily.com/articles/14434/20130328/cancer-treatment-cd47miracle-bullet-breast-colon-bladder-antibody-eat-macrophage-immune.htm>